Tianda Pharmaceuticals Ltd. (HK:0455)
:0455
Top Page
Tianda Pharmaceuticals Ltd.
(0455)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$0.10
▼(-24.62% Downside)
Action:ReiteratedDate:01/08/26
The score is primarily held down by weak financial performance, including declining revenue, ongoing losses, and negative operating cash flow. Technical indicators are mixed with only modest near-term improvement against a longer-term downtrend, while valuation is constrained by negative earnings (negative P/E) and no provided dividend yield.
Positive Factors
Diversified revenue streams
Tianda's revenue model spans prescription drugs, OTC products and traditional Chinese medicine plus licensing and distribution partnerships. This diversification reduces dependence on a single product or channel, supporting steadier demand and resilience across healthcare segments over months.
Negative Factors
Declining revenue
A sharp revenue decline (-14.23%) erodes scale and bargaining power, squeezing gross margins and reducing funds available for R&D, marketing and commercialization. Continued top-line contraction would undermine long-term competitiveness and investment capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified revenue streams
Tianda's revenue model spans prescription drugs, OTC products and traditional Chinese medicine plus licensing and distribution partnerships. This diversification reduces dependence on a single product or channel, supporting steadier demand and resilience across healthcare segments over months.
Read all positive factors
Tianda Pharmaceuticals Ltd. (0455) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$208.55M
Dividend YieldN/A
Average Volume (3M)84.94K
Price to Earnings (P/E)―
Beta (1Y)0.37
Revenue Growth-19.28%
EPS Growth-42.27%
CountryHK
Employees701
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,150,041,700
10 Day Avg. Volume115,400
30 Day Avg. Volume84,945
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.72
Price to Sales (P/S)1.10
P/FCF Ratio-6.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Tianda Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Tianda Pharmaceuticals Limited, an investment holding company, engages in the research and development, production, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia. Its product range i...
How the Company Makes Money
Tianda Pharmaceuticals generates revenue through multiple streams, including the sale of prescription medications, OTC products, and traditional Chinese medicine. The company's revenue model is based on direct sales to healthcare providers, pharma...
Tianda Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 384.68M | 329.94M | 532.09M | 546.69M | 509.96M | 474.33M |
| Gross Profit | 176.28M | 152.02M | 255.53M | 251.52M | 241.22M | 258.99M |
| EBITDA | -9.97M | -49.49M | 15.66M | -19.89M | -5.14M | -6.25M |
| Net Income | -47.26M | -61.37M | -24.16M | -54.64M | -21.67M | -25.92M |
Balance Sheet | ||||||
| Total Assets | 804.77M | 765.02M | 917.29M | 1.09B | 1.16B | 1.13B |
| Cash, Cash Equivalents and Short-Term Investments | 103.77M | 85.69M | 162.44M | 343.44M | 334.00M | 234.98M |
| Total Debt | 98.81M | 127.44M | 113.60M | 141.05M | 160.43M | 145.53M |
| Total Liabilities | 260.34M | 259.36M | 325.35M | 434.23M | 375.08M | 342.97M |
| Stockholders Equity | 544.55M | 505.84M | 592.07M | 627.83M | 756.75M | 756.71M |
Cash Flow | ||||||
| Free Cash Flow | -43.08M | -52.30M | -116.04M | 54.73M | -61.98M | -184.08M |
| Operating Cash Flow | -26.10M | -9.70M | -49.76M | 79.11M | -8.23M | -37.63M |
| Investing Cash Flow | -42.53M | -31.77M | -69.10M | -12.20M | 86.35M | -137.73M |
| Financing Cash Flow | -59.61M | -30.65M | -57.39M | -28.98M | -1.29M | 90.75M |
Tianda Pharmaceuticals Ltd. Technical Analysis
Neutral
0.13
Price Trends
0.10
Negative
0.11
Negative
0.13
Negative
Market Momentum
>-0.01
Negative
45.16
Neutral
73.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0455, the sentiment is Neutral. The current price of 0.13 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.10, and below the 200-day MA of 0.13, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.16 is Neutral, neither overbought nor oversold. The STOCH value of 73.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0455.
Tianda Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | HK$206.39M | -6.04 | -6.17% | 3.51% | -5.98% | -81.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$926.38M | -2.84 | -48.86% | ― | -43.46% | -96.48% | |
48 Neutral | HK$683.28M | -17.91 | 20.98% | ― | ― | ― | |
48 Neutral | HK$177.84M | -40.12 | -8.95% | ― | 2.54% | 33.33% | |
46 Neutral | HK$416.29M | 43.63 | -1.17% | 7.50% | 59.60% | -351.02% | |
44 Neutral | HK$208.55M | -3.96 | -11.18% | ― | -19.28% | -42.27% |
* Healthcare Sector Average
HK:0455
Tianda Pharmaceuticals Ltd.
0.10
-0.07
-42.26%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.37
0.02
5.71%
HK:1011
China NT Pharma Group Co., Ltd.
0.72
0.49
213.04%
HK:1652
Fusen Pharmaceutical Co., Ltd.
1.26
1.02
425.00%
HK:8329
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H
0.12
-0.02
-15.75%
HK:8622
Huakang Biomedical Holdings Company Limited
0.35
0.05
18.97%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.